Gen- und RNA-Therapie in der Neurologie

Gen- und RNA-Therapien ermöglichen erstmals kausale Behandlungsansätze für genetisch bedingte neurologische Erkrankungen. Dieser Beitrag gibt einen praxisnahen Überblick über molekulare Therapieansätze und zeigt, wie sich die neurologische Versorgung durch Präzisionsmedizin verändert: Im Fokus stehen Wirkmechanismen, zugelassene Therapien, zukünftige Entwicklungen, Gentherapie, Antisense-Oligonukleotide und Stammzelltransplantation.

Schlüsselwörter

Gentherapie - RNA-Therapie - molekulare Präzisionsmedizin - genetische neurologische Erkrankungen - Antisense-Oligonukleotide

• Literatur

• 1 Garcia-Gonzalez N, Goncalves-Sanchez J, Gomez-Nieto R. et al. Advances and challenges in gene therapy for neurodegenerative diseases: a systematic review. Int J Mol Sci 2024; 25: 12485
• 2 Shademan B, Biray Avci C, Nikanfar M. et al. Application of next-generation sequencing in neurodegenerative diseases: opportunities and challenges. Neuromolecular Med 2021; 23: 225-235
• 3 Fischell JM, Fishman PS. A multifaceted approach to optimizing AAV delivery to the brain for the treatment of neurodegenerative diseases. Front Neurosci 2021; 15: 747726
• 4 Duan D. Duchenne muscular dystrophy gene therapy in 2023: status, perspective, and beyond. Hum Gene Ther 2023; 34: 345-349
• 5 Foster K, Foster H, Dickson JG. Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 2006; 13: 1677-1685
• 6 Gertz MA, Mauermann ML, Grogan M. et al. Advances in the treatment of hereditary transthyretin amyloidosis: a review. Brain Behav 2019; 9: e01371
• 7 Chongmelaxme B, Yodsurang V, Vichayachaipat P. et al. Gene-based therapy for the treatment of spinal muscular atrophy types 1 and 2 : a systematic review and meta-analysis. Gene Ther 2024;
• 8 Ogbonmide T, Rathore R, Rangrej SB. et al. Gene therapy for Spinal Muscular Atrophy (SMA): a review of current challenges and safety considerations for onasemnogene abeparvovec (Zolgensma). Cureus 2023; 15: e36197
• 9 Castle MJ, Baltanas FC, Kovacs I. et al. Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer's disease identifies a need for improved vector delivery. Hum Gene Ther 2020; 31: 415-422
• 10 Feneberg E, Otto M. Genspezifische Therapieansätze bei der Alzheimer-Krankheit und anderen Tauopathien. Nervenarzt 2020; 91: 312-317
• 11 Kim YK. RNA therapy. Exp Mol Med 2023; 55: 1281-1282
• 12 Liu M, Wang Y, Zhang Y. et al. Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct Target Ther 2025; 10: 73
• 13 Miller TM, Cudkowicz ME, Genge A. et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 2022; 387: 1099-1110
• 14 Ludolph A, Wiesenfarth M. Tofersen and other antisense oligonucleotides in ALS. Ther Adv Neurol Disord 2025; 18: 17562864251313915
• 15 de Vasconcelos P, Lacerda JF. Hematopoietic stem cell transplantation for neurological disorders: a focus on inborn errors of metabolism. Front Cell Neurosci 2022; 16: 895511
• 16 Fumagalli F, Calbi V, Gallo V. et al. Long-term effects of atidarsagene autotemcel for metachromatic leukodystrophy. N Engl J Med 2025; 392: 1609-1620
• 17 Zhang Z, Jiang H, Huang L. et al. Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: a long-term follow-up pilot study. Protein Cell 2025; 16: 16-27
• 18 Kim J, Hu C, Moufawad El Achkar C. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med 2019; 381: 1644-1652